0001065078 2026-01-01 2026-06-30 0001065078 2026-08-03 0001065078 2026-06-30 0001065078 2025-12-31 0001065078 2026-04-01 2026-06-30 0001065078 2025-04-01 2025-06-30 0001065078 2025-01-01 2025-06-30 0001065078 us-gaap:CommonStockMember 2025-12-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001065078 us-gaap:RetainedEarningsMember 2025-12-31 0001065078 us-gaap:CommonStockMember 2026-03-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001065078 us-gaap:RetainedEarningsMember 2026-03-31 0001065078 2026-03-31 0001065078 us-gaap:CommonStockMember 2024-12-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001065078 us-gaap:RetainedEarningsMember 2024-12-31 0001065078 2024-12-31 0001065078 us-gaap:CommonStockMember 2025-03-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001065078 us-gaap:RetainedEarningsMember 2025-03-31 0001065078 2025-03-31 0001065078 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001065078 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001065078 2026-01-01 2026-03-31 0001065078 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001065078 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001065078 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001065078 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001065078 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001065078 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001065078 2025-01-01 2025-03-31 0001065078 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001065078 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001065078 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001065078 us-gaap:CommonStockMember 2026-06-30 0001065078 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001065078 us-gaap:RetainedEarningsMember 2026-06-30 0001065078 us-gaap:CommonStockMember 2025-06-30 0001065078 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001065078 us-gaap:RetainedEarningsMember 2025-06-30 0001065078 2025-06-30 0001065078 nssi:ILiADBiotechnologiesLLCMember 2026-06-30 0001065078 nssi:LitigationSettlementsMember 2026-01-01 2026-06-30 0001065078 nssi:LitigationSettlementsMember 2025-01-01 2025-06-30 0001065078 nssi:LitigationSettlementsMember 2026-04-01 2026-06-30 0001065078 nssi:LitigationSettlementsMember 2025-04-01 2025-06-30 0001065078 srt:MinimumMember 2026-06-30 0001065078 srt:MaximumMember 2026-06-30 0001065078 srt:MinimumMember 2026-01-01 2026-06-30 0001065078 srt:MaximumMember 2026-01-01 2026-06-30 0001065078 nssi:StockIncentivePlan2022Member 2026-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001065078 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001065078 nssi:CostBasisMember 2026-06-30 0001065078 nssi:GrossUnrealizedGainsMember 2026-06-30 0001065078 nssi:GrossUnrealizedLossesMember 2026-06-30 0001065078 nssi:FairValueMember 2026-06-30 0001065078 nssi:CostBasisMember 2025-12-31 0001065078 nssi:GrossUnrealizedGainsMember 2025-12-31 0001065078 nssi:GrossUnrealizedLossesMember 2025-12-31 0001065078 nssi:FairValueMember 2025-12-31 0001065078 2025-03-01 2025-03-31 0001065078 srt:ChiefExecutiveOfficerMember nssi:PriorEmploymentAgreementMember 2022-03-01 2022-03-22 0001065078 us-gaap:PrivatePlacementMember 2026-02-04 2026-02-05 0001065078 us-gaap:PrivatePlacementMember 2026-06-30 0001065078 us-gaap:PrivatePlacementMember 2026-01-01 2026-06-30 0001065078 us-gaap:CommonStockMember 2026-06-30 0001065078 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001065078 nssi:SeriesA1PreferredStockMember 2026-06-30 0001065078 2025-06-17 0001065078 2011-08-01 2026-06-30 0001065078 2026-06-29 0001065078 2022-08-01 2022-08-16 0001065078 nssi:BoardOfDirectorsMember 2026-01-01 2026-06-30 iso4217:USD shares iso4217:USD shares pure nssi:Integer false 2026 Q2 --12-31 0001065078

10-Q true 2026-06-30 false 1-15288 NETWORK-1 TECHNOLOGIES, INC. DE 11-3027591 65 Locust Avenue Third Floor New Canaan CT 06840 203 920-1055 Common Stock, par value $0.01 per share NTIP NYSE Yes Yes Non-accelerated Filer true false false false 22863181

9435000

13402000

24317000

23467000

149000

237000

33901000

37106000

1766000

1479000

2786000

1734000

13000

4565000

3226000

38466000

40332000

656000

253000

289000

66000

228000

722000

770000

245000

967000

770000

0.01

10000000

0.01

50000000

22863181

22824009

229000

228000

62672000

63426000

-25402000

-24092000

37499000

39562000

38466000

40332000

150000

42000

481000

164000

1256000

285000

488000

519000

1084000

1121000

44000

37000

88000

67000

1013000

720000

2428000

1515000

-1013000

-720000

-2428000

-1365000

350000

445000

734000

929000

1052000

8000 22000 -279000 171000

358000

467000

1507000

1100000

-655000

-253000

-921000

-265000

-31000

-38000

245000

-149000

-69000

245000

-180000

-655000 -184000 -1166000 -85000

-279000

-741000

-655000

-463000

-1166000

-826000

-0.03

-0.02

-0.05

-0.04

-0.03

-0.02

-0.05

-0.04

22836456

22873907

22824937

22883729

22836456

22873907

22824937

22883729

0.05

22824009

228000

63426000

-24092000

39562000

998000 998000

79000

40000 1000 -1000 7130 9000 9000 60996 1000 84000 85000

-511000

22795883

228000

62506000

-24696000

38038000

42000

7500

94778

1000

124000

125000

34980 51000 51000

-655000

22863181

229000

62672000

-25402000

37499000

22961619

229000

65455000

-21373000

44311000

1171000 1171000

81000

32500 5348 7000 7000 106662 1000 149000 150000

-363000

22882109

228000

64365000

-21892000

42701000

80000

7500 44811 57000 57000

-463000

22844798

228000

64445000

-22412000

42261000

-1166000

-826000

88000

67000

121000

161000

1052000 -741000

245000

-149000

27000

-340000

170000

-88000

-52000

403000

1000

-24000

-309000

-382000

-1242000

-502000

-5110000 -7554000

6300000

4990000

250000

414000

-1440000

2150000

1140000

1155000

9000 7000

136000

207000

-1285000

-1369000

-3967000

279000

13402000

13145000

9435000

13424000

-142000 27000 -125000

NOTE A – BASIS OF PRESENTATION AND NATURE OF BUSINESS [1]     BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited, but, in the opinion of the management of Network-1 Technologies, Inc. (the “Company”), contain all adjustments consisting only of normal recurring items which the Company considers necessary for the fair presentation of the Company’s financial position as of June 30, 2026, and the results of its operations, its statement of cash flows and its changes in stockholders’ equity for the three and six month periods ended June 30, 2026 and June 30, 2025. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP may have been omitted pursuant to such rules and regulations, although management believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2026. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results of operations to be expected for the full year. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Mirror Worlds Technologies, LLC and HFT Solutions, LLC. All intercompany balances and transactions have been eliminated in consolidation. [2]     BUSINESS The Company is engaged in the development, licensing and protection of its intellectual property assets. The Company presently owns one-hundred twenty-one (121) U.S. patents, fifty-four (54) of which have expired, and fifteen (15) international patents related to (i) the M2M/IoT patent portfolio (the “M2M/IoT Patent Portfolio”) relating to, among other things, enabling technology for authenticating and using eSIM (embedded Subscriber Identification Module) technology in Internet of Things (“IoT”), Machine-to-Machine, and other mobile devices, including smartphones, tablets and computers, as well as automobiles; (ii) the HFT patent portfolio (the “HFT Patent Portfolio”) covering certain advanced technologies relating to high frequency trading, which inventions specifically address technological problems associated with speed and latency and provide critical latency gains in trading systems; (iii) the Cox patent portfolio (the “Cox Patent Portfolio”) relating to enabling technology for identifying media content on the Internet and taking further actions to be performed after such identification; and (iv) the smart home patent portfolio (the “Smart Home Patent Portfolio”) relating to, among other things, the enabling technology to support the interoperability of smart home IoT devices. The Company’s current strategy includes continuing to pursue licensing opportunities for its patent portfolios. In addition, the Company reviews opportunities to acquire or license additional intellectual property as well as other strategic alternatives. The Company’s patent acquisition and development strategy is to focus on acquiring high quality patents which management believes have the potential to generate significant licensing opportunities as the Company had achieved with respect to its Remote Power Patent and Mirror Worlds Patent Portfolio. In addition, the Company may also enter into strategic relationships with third parties to develop, commercialize, license or otherwise monetize their intellectual property. The Company has also made equity investments totaling $7,000,000 in ILiAD Biotechnologies, Inc. (“ILiAD”, formerly ILiAD Biotechnologies, LLC), a clinical stage biotechnology company (see Note K hereof).

121

54 15

7000000

NOTE B – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [1]      Use of Estimates and Assumptions The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. The significant estimates and assumptions made in the preparation of the Company’s unaudited condensed consolidated financial statements include costs related to the Company’s assertion of litigation, the valuation and carrying value of the Company’s equity investment, valuation of the Company’s patent portfolios, stock-based compensation and the recoverability of deferred tax assets. Actual results could be materially different from those estimates upon which the carrying values were based. [2]   Revenue Recognition In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), revenue is recognized in accordance with ASC 606 - Revenue from Contracts with Customers. Revenue is recognized when the Company completes the licensing of its intellectual property to its licensees, obtains a final judgment (after all appeals have been exhausted) or enters into a litigation settlement agreement involving any of its expired patents. With respect to licensing its intellectual property, final judgment or a litigation settlement, revenue is recognized in an amount that reflects the consideration the Company expects to be entitled to in exchange for licensing its intellectual property, the final judgment or litigation settlement. The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">identification of the license agreement, final judgment or litigation settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">identification of the performance obligations in the license agreement, final judgment or litigation settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">determination of the consideration for the license agreement, final judgment or settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">allocation of the transaction price to the performance obligations in the contract; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">recognition of revenue when the Company satisfies its performance obligations.</td></tr></table> Revenue disaggregated by source is as follows: <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--DisaggregationOfRevenueTableTextBlock_zsMfkDgfn6gj" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of revenue disaggregated by source</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260101__20260630_zyCC3flwADel" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20250101__20250630_zOIzQxnCunti" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20260401__20260630_z5yGGjr6qPt2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20250401__20250630_zrzCqjxyAFZk" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; font-weight: bold; text-align: center"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 40%; text-align: left; padding-left: 5.4pt"> Litigation settlements </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">150,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_z9hH7gKntaod" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Revenue from the Company’s patent licensing and enforcement business is typically generated from negotiated license agreements, final judgment or settlement agreements as a result of litigation involving the Company’s patents. The timing and amount of revenue recognized from each licensee or from final judgment or settlement agreement depends upon a variety of factors, including the terms of each agreement and the nature of the obligations of the parties. These agreements may include, but are limited to, elements related to past infringement liabilities, non-refundable upfront license fees, and ongoing royalties on licensed products sold by the licensee. Generally, in the event of settlement of litigation related to the Company’s assertion of patent infringement involving its intellectual property, defendants will either pay (i) a non-refundable lump sum payment for a non-exclusive fully-paid license, (ii) a non-refundable lump sum payment (license initiation fee) together with an ongoing obligation to pay quarterly or monthly royalties to the Company for the life of the licensed patent, or (iii) a lump sum settlement payment with respect to litigation involving the Company’s patents. Fully-paid licenses provide for a non-refundable up-front payment for which the Company has no future obligations or performance requirements, revenue is generally recognized when the Company has obtained the signed license agreement, all performance obligations have been substantially performed, amounts are fixed and determinable, and collectability is reasonably assured. Revenue from fully-paid licenses may consist of one or more installments. The timing and amount of revenue recognized from each licensee depends upon a number of factors including the specific terms of each agreement and the nature of the deliverables and obligations. [3]   Equity Investments Investments accounted for under the equity method are equity securities in entities the Company does not control but over which it has the ability to exercise significant influence. These investments are accounted for under the equity method of accounting in accordance with ASC 323 - Investments — Equity Method and Joint Ventures. Equity method investments are measured at cost minus impairment, if any, plus or minus the Company’s share of an investee’s income or loss. The Company’s proportionate share of the income or loss from equity method investments is recognized on a one-quarter lag. Investments accounted for under the cost method are accounted for in accordance with ASC 321, Investments – Equity Securities (“ASC 321”). Under this guidance, investments in equity securities in privately-held companies without readily determinable fair values are generally recorded at cost, plus or minus subsequent observable price changes in identical or similar investments, less impairments. As a part of the assessment for impairment indicators, the Company considers significant deterioration in the earnings performance and overall business prospects of the investee, as well as significant adverse changes in the external environment in which the investment operates. If qualitative assessment indicates the carrying value of the investment is impaired, the fair value of the investments would be estimated, which would involve a significant degree of judgment and subjectivity. The Company evaluates the investment on a quarterly basis for such indicators of impairment or observable price changes in orderly transactions for the same or similar investments. Changes in fair value are reported in Other Income (Expense) in the unaudited condensed consolidated statements of operations (See Note K hereof). [4]      Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (ASC 740), which requires the Company to use the assets and liability method of accounting for income taxes. Under the assets and liability method, deferred income taxes are recognized for the tax consequences of temporary(timing) differences by applying enacted statutory tax rates applicable to future years to differences between financial statement carrying amounts and the tax bases of existing assets and liabilities and operating loss and tax credit carry forwards. Under this accounting standard, the effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. As of June 30, 2026, the Company had total deferred tax assets generated from its activities of $2,355,000. The Company’s deferred tax assets were offset by a valuation allowance of $2,355,000 as it was determined that it is more likely than not that certain deferred tax assets will not be realized. As of June 30, 2026, the Company also had a deferred tax liability of $245,000. The personal holding company (“PHC”) rules under the Internal Revenue Code impose a 20% tax on a PHC’s undistributed personal holding company income (“UPHCI”), which means, in general, taxable income subject to certain adjustments and reduced by certain distributions to shareholders. For a corporation to be classified as a PHC, it must satisfy two tests: (i) that more than 50% in value of its outstanding shares must be owned directly or indirectly by five or fewer individuals at any time during the second half of the year (after applying constructive ownership rules to attribute stock owned by entities to their beneficial owners and among certain family members and other related parties) (the “Ownership Test”) and (ii) at least 60% of its adjusted ordinary gross income for a taxable year consists of dividends, interest, royalties, annuities and rents (the “Income Test”). As of July 15, 2026, based on available information concerning the Company’s shareholder ownership, the Company did not satisfy the Ownership Test or the Income Test. However, the Company may subsequently be determined to be a PHC in 2026 or in future years if it satisfies both the Ownership Test and Income Test. If the Company were to become a PHC in 2026 or any future year, it would be subject to the 20% tax on its UPHCI. In such event, the Company may issue a special cash dividend to its shareholders in an amount equal to the UPHCI rather than incur the 20% tax. ASC 740-10 - Accounting for Uncertainty in Income Taxes, defines uncertainty in income taxes and the evaluation of a tax position as a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. The Company had no uncertain tax positions as of June 30, 2026. U.S. federal, state and local income tax returns prior to 2022 are not subject to examination by any applicable tax authorities, except that tax authorities could challenge returns (only under certain circumstances) for earlier years to the extent they generated loss carry-forwards that are available for those future years. [5]     Segment Reporting The Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”) reviews and assesses performance. The Company’s Chief Executive Officer is the CODM. The primary financial measures used by the CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). Such measures are used to evaluate the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Net loss and Operating loss are disclosed in the unaudited condensed consolidated statements of operations. Segment expenses and other segment items are provided to the CODM on the same basis as disclosed in the unaudited condensed consolidated statements of operations. The Company has a single reporting segment. [6]     Recent Accounting Pronouncements Disaggregation of Income Statement Expenses In November 2024, the FASB issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires additional information about specific expenses in certain notes to the Consolidated Financial Statements. The guidance will be effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine its impact on the Company's disclosures. Income Tax Disclosure In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirements became effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the year ended December 31, 2025. The adoption of this guidance did not have a material impact on the Company’s financial statements and related disclosures.

[1]      Use of Estimates and Assumptions The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. The significant estimates and assumptions made in the preparation of the Company’s unaudited condensed consolidated financial statements include costs related to the Company’s assertion of litigation, the valuation and carrying value of the Company’s equity investment, valuation of the Company’s patent portfolios, stock-based compensation and the recoverability of deferred tax assets. Actual results could be materially different from those estimates upon which the carrying values were based.

[2]   Revenue Recognition In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), revenue is recognized in accordance with ASC 606 - Revenue from Contracts with Customers. Revenue is recognized when the Company completes the licensing of its intellectual property to its licensees, obtains a final judgment (after all appeals have been exhausted) or enters into a litigation settlement agreement involving any of its expired patents. With respect to licensing its intellectual property, final judgment or a litigation settlement, revenue is recognized in an amount that reflects the consideration the Company expects to be entitled to in exchange for licensing its intellectual property, the final judgment or litigation settlement. The Company determines revenue recognition through the following steps: <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">identification of the license agreement, final judgment or litigation settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">identification of the performance obligations in the license agreement, final judgment or litigation settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">determination of the consideration for the license agreement, final judgment or settlement agreement;</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 3pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">allocation of the transaction price to the performance obligations in the contract; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0.6in"></td><td style="width: 0.25in">•</td><td style="text-align: justify">recognition of revenue when the Company satisfies its performance obligations.</td></tr></table> Revenue disaggregated by source is as follows: <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--DisaggregationOfRevenueTableTextBlock_zsMfkDgfn6gj" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of revenue disaggregated by source</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260101__20260630_zyCC3flwADel" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20250101__20250630_zOIzQxnCunti" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20260401__20260630_z5yGGjr6qPt2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20250401__20250630_zrzCqjxyAFZk" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; font-weight: bold; text-align: center"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 40%; text-align: left; padding-left: 5.4pt"> Litigation settlements </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">150,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_z9hH7gKntaod" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Revenue from the Company’s patent licensing and enforcement business is typically generated from negotiated license agreements, final judgment or settlement agreements as a result of litigation involving the Company’s patents. The timing and amount of revenue recognized from each licensee or from final judgment or settlement agreement depends upon a variety of factors, including the terms of each agreement and the nature of the obligations of the parties. These agreements may include, but are limited to, elements related to past infringement liabilities, non-refundable upfront license fees, and ongoing royalties on licensed products sold by the licensee. Generally, in the event of settlement of litigation related to the Company’s assertion of patent infringement involving its intellectual property, defendants will either pay (i) a non-refundable lump sum payment for a non-exclusive fully-paid license, (ii) a non-refundable lump sum payment (license initiation fee) together with an ongoing obligation to pay quarterly or monthly royalties to the Company for the life of the licensed patent, or (iii) a lump sum settlement payment with respect to litigation involving the Company’s patents. Fully-paid licenses provide for a non-refundable up-front payment for which the Company has no future obligations or performance requirements, revenue is generally recognized when the Company has obtained the signed license agreement, all performance obligations have been substantially performed, amounts are fixed and determinable, and collectability is reasonably assured. Revenue from fully-paid licenses may consist of one or more installments. The timing and amount of revenue recognized from each licensee depends upon a number of factors including the specific terms of each agreement and the nature of the deliverables and obligations.

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--DisaggregationOfRevenueTableTextBlock_zsMfkDgfn6gj" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of revenue disaggregated by source</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260101__20260630_zyCC3flwADel" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20250101__20250630_zOIzQxnCunti" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20260401__20260630_z5yGGjr6qPt2" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20250401__20250630_zrzCqjxyAFZk" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; font-weight: bold; text-align: center"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 40%; text-align: left; padding-left: 5.4pt"> Litigation settlements </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">150,000</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 3%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right">—</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Revenues_z9hH7gKntaod" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

150000

[3]   Equity Investments Investments accounted for under the equity method are equity securities in entities the Company does not control but over which it has the ability to exercise significant influence. These investments are accounted for under the equity method of accounting in accordance with ASC 323 - Investments — Equity Method and Joint Ventures. Equity method investments are measured at cost minus impairment, if any, plus or minus the Company’s share of an investee’s income or loss. The Company’s proportionate share of the income or loss from equity method investments is recognized on a one-quarter lag. Investments accounted for under the cost method are accounted for in accordance with ASC 321, Investments – Equity Securities (“ASC 321”). Under this guidance, investments in equity securities in privately-held companies without readily determinable fair values are generally recorded at cost, plus or minus subsequent observable price changes in identical or similar investments, less impairments. As a part of the assessment for impairment indicators, the Company considers significant deterioration in the earnings performance and overall business prospects of the investee, as well as significant adverse changes in the external environment in which the investment operates. If qualitative assessment indicates the carrying value of the investment is impaired, the fair value of the investments would be estimated, which would involve a significant degree of judgment and subjectivity. The Company evaluates the investment on a quarterly basis for such indicators of impairment or observable price changes in orderly transactions for the same or similar investments. Changes in fair value are reported in Other Income (Expense) in the unaudited condensed consolidated statements of operations (See Note K hereof).

[4]      Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (ASC 740), which requires the Company to use the assets and liability method of accounting for income taxes. Under the assets and liability method, deferred income taxes are recognized for the tax consequences of temporary(timing) differences by applying enacted statutory tax rates applicable to future years to differences between financial statement carrying amounts and the tax bases of existing assets and liabilities and operating loss and tax credit carry forwards. Under this accounting standard, the effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. As of June 30, 2026, the Company had total deferred tax assets generated from its activities of $2,355,000. The Company’s deferred tax assets were offset by a valuation allowance of $2,355,000 as it was determined that it is more likely than not that certain deferred tax assets will not be realized. As of June 30, 2026, the Company also had a deferred tax liability of $245,000. The personal holding company (“PHC”) rules under the Internal Revenue Code impose a 20% tax on a PHC’s undistributed personal holding company income (“UPHCI”), which means, in general, taxable income subject to certain adjustments and reduced by certain distributions to shareholders. For a corporation to be classified as a PHC, it must satisfy two tests: (i) that more than 50% in value of its outstanding shares must be owned directly or indirectly by five or fewer individuals at any time during the second half of the year (after applying constructive ownership rules to attribute stock owned by entities to their beneficial owners and among certain family members and other related parties) (the “Ownership Test”) and (ii) at least 60% of its adjusted ordinary gross income for a taxable year consists of dividends, interest, royalties, annuities and rents (the “Income Test”). As of July 15, 2026, based on available information concerning the Company’s shareholder ownership, the Company did not satisfy the Ownership Test or the Income Test. However, the Company may subsequently be determined to be a PHC in 2026 or in future years if it satisfies both the Ownership Test and Income Test. If the Company were to become a PHC in 2026 or any future year, it would be subject to the 20% tax on its UPHCI. In such event, the Company may issue a special cash dividend to its shareholders in an amount equal to the UPHCI rather than incur the 20% tax. ASC 740-10 - Accounting for Uncertainty in Income Taxes, defines uncertainty in income taxes and the evaluation of a tax position as a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. The Company had no uncertain tax positions as of June 30, 2026. U.S. federal, state and local income tax returns prior to 2022 are not subject to examination by any applicable tax authorities, except that tax authorities could challenge returns (only under certain circumstances) for earlier years to the extent they generated loss carry-forwards that are available for those future years.

2355000

245000

[5]     Segment Reporting The Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”) reviews and assesses performance. The Company’s Chief Executive Officer is the CODM. The primary financial measures used by the CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). Such measures are used to evaluate the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Net loss and Operating loss are disclosed in the unaudited condensed consolidated statements of operations. Segment expenses and other segment items are provided to the CODM on the same basis as disclosed in the unaudited condensed consolidated statements of operations. The Company has a single reporting segment.

[6]     Recent Accounting Pronouncements Disaggregation of Income Statement Expenses In November 2024, the FASB issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU requires additional information about specific expenses in certain notes to the Consolidated Financial Statements. The guidance will be effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine its impact on the Company's disclosures. Income Tax Disclosure In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The new requirements became effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the year ended December 31, 2025. The adoption of this guidance did not have a material impact on the Company’s financial statements and related disclosures.

NOTE C – PATENTS The Company’s intangible assets at June 30, 2026 include patents with estimated remaining economic useful lives ranging from approximately 7 to 13 years. For all periods presented, all of the Company’s unexpired patents were subject to amortization. The gross carrying amounts and accumulated amortization related to acquired intangible assets as of June 30, 2026 and December 31, 2025 were as follows: <table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zYWYdccoYhmh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - PATENTS (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of patent</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630_z7bpF7eKzRVh" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20251231_zG0sm3ow7CDa" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_zSBPyLiD2Mqd" style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt"> Gross carrying amount – patents</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,262,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,887,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_zKpsDo6XQ763" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated amortization – patents</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,496,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,408,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_zrNIm2yt3o72" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Patents, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,766,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,479,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Amortization expense for the three months ended June 30, 2026 and 2025 was $44,000 and $37,000, respectively. Amortization expense for the six months ended June 30, 2026 and 2025 was $88,000 and $67,000, respectively. Future amortization of intangible assets for the next five years and thereafter is as follows: <table cellpadding="0" cellspacing="5" id="xdx_88E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBYjDrpIUq4j" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - PATENTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">Schedule of future amortization of intangible assets</td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td id="xdx_49B_20260630_zpQX1WlE7ecl" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="text-align: left">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzzmo_zLust13dqP23" style="vertical-align: bottom"> <td style="width: 32%; font-size: 12pt; text-align: left">2026 – remaining </td><td style="width: 4%; font-size: 12pt; text-align: left"> </td><td style="width: 1%; font-size: 12pt"> </td> <td style="width: 7%; font-size: 12pt; text-align: left">$</td><td style="width: 24%; font-size: 12pt; text-align: right">88,000</td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzzmo_z9vfjeeAFZZ4" style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">2027</td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right">174,000</td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzzmo_zt4hS0U38Vzj" style="vertical-align: bottom"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzzmo_zdPoGv4bcdI4" style="vertical-align: bottom"> <td style="text-align: left">2029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzzmo_zC3WDPLmPPLk" style="vertical-align: bottom"> <td style="text-align: left">2030</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzzmo_zX2hZln3RLn8" style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left">Thereafter</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">991,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzzmo_zyyXv9OtaEj8" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,766,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> The expiration dates of patents within the Company’s M2M/IoT Patent Portfolio range from <span id="xdx_905_ecustom--ExpirationDatesOfPatentsWithinCompanysM2miotPatentPortfolio_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zN00X8034F77" title="Expiration dates of the patents within the Company's M2M/IoT Patent Portfolio">September 2033 to <span id="xdx_903_ecustom--ExpirationDatesOfPatentsWithinCompanysM2miotPatentPortfolio_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_z5g9ztQK6c4" title="Expiration dates of the patents within the Company's M2M/IoT Patent Portfolio">December 2034. The expiration dates of patents within the Company’s HFT Patent Portfolio range from <span id="xdx_904_ecustom--ExpirationDatesWithinCompanysHftPatentPortfolio_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zuzBA7leZdij" title="Expiration dates within Company's HFT patent portfolio">October 2039 to <span id="xdx_90C_ecustom--ExpirationDatesWithinCompanysHftPatentPortfolio_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zQd7pZyOBXk4" title="Expiration dates within Company's HFT patent portfolio">February 2040. The expiration dates of patents within the Company’s Smart Home Patent Portfolio range from <span id="xdx_90C_ecustom--ExpirationDatesWithinCompanysSmartHomePatent_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zcnTIhvEFQB2" title="Expiration dates within Company's Smart Home patent portfolio">May 2039 to <span id="xdx_902_ecustom--ExpirationDatesWithinCompanysSmartHomePatent_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zmk0DKwkYfG8" title="Expiration dates within Company's Smart Home patent portfolio">May 2040. All of the patents within the Company’s Mirror Worlds Patent Portfolio, Cox Patent Portfolio and the Remote Power Patent have expired.

P7Y

P13Y

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zYWYdccoYhmh" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - PATENTS (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of patent</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260630_z7bpF7eKzRVh" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49A_20251231_zG0sm3ow7CDa" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_zSBPyLiD2Mqd" style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt"> Gross carrying amount – patents</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">9,262,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,887,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_zKpsDo6XQ763" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Accumulated amortization – patents</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,496,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,408,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_zrNIm2yt3o72" style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Patents, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,766,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,479,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

9262000

8887000

7496000

7408000

1766000

1479000

44000

37000

88000

67000

<table cellpadding="0" cellspacing="5" id="xdx_88E_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zBYjDrpIUq4j" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - PATENTS (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">Schedule of future amortization of intangible assets</td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td id="xdx_49B_20260630_zpQX1WlE7ecl" style="font-size: 12pt; text-align: center"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="text-align: left">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzzmo_zLust13dqP23" style="vertical-align: bottom"> <td style="width: 32%; font-size: 12pt; text-align: left">2026 – remaining </td><td style="width: 4%; font-size: 12pt; text-align: left"> </td><td style="width: 1%; font-size: 12pt"> </td> <td style="width: 7%; font-size: 12pt; text-align: left">$</td><td style="width: 24%; font-size: 12pt; text-align: right">88,000</td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzzmo_z9vfjeeAFZZ4" style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">2027</td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right">174,000</td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzzmo_zt4hS0U38Vzj" style="vertical-align: bottom"> <td style="text-align: left">2028</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzzmo_zdPoGv4bcdI4" style="vertical-align: bottom"> <td style="text-align: left">2029</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzzmo_zC3WDPLmPPLk" style="vertical-align: bottom"> <td style="text-align: left">2030</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">171,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_maFLIANzzmo_zX2hZln3RLn8" style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left">Thereafter</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">991,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzzmo_zyyXv9OtaEj8" style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,766,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

88000

174000

171000

991000

1766000

September 2033 December 2034 October 2039 February 2040 May 2039 May 2040

NOTE D – STOCKHOLDERS’ EQUITY Stock Incentive Plan The Company adopted the 2022 Stock Incentive Plan, (the “2022 Plan”) upon approval by its Board of Directors on July 25, 2022 and its stockholders on September 20, 2022. The 2022 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock, (d) stock appreciation rights, and (e) other stock-based awards including restricted stock units. As of June 30, 2026, there were 125,000 shares of common stock subject to outstanding awards under the 2022 Plan and 1,920,000 shares of common stock available for issuance under the 2022 Plan. Restricted Stock Units A summary of restricted stock unit activity for the three months ended June 30, 2026 is as follows (each restricted stock unit issued by the Company represents the right to receive one share of the Company’s common stock): <table cellpadding="0" cellspacing="2" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLpGaSiEv2o4" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of stock option activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Grants of restricted stock units"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Grants of restricted stock units, weighted average grant date fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt"> Balance of restricted stock units outstanding at December 31, 2025</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20260101__20260630_zTlTjiypnuBa" style="width: 12%; text-align: right" title="Restricted stock units, outstanding number of units, beginning balance">512,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260630_zOU71zXrBgF6" style="width: 12%; text-align: right" title="Restricted stock units, weighted average grant date fair value, beginning balance">1.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Grants of restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260101__20260630_zpoKrFDXcXKc" style="text-align: right" title="Grants of restricted stock units">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--IssuanceWeightedaverageGrantDateFairValue_c20260101__20260630_zNIiRg2P1SJl" style="text-align: right" title="Grants of restricted stock units, weighted average grant date fair value">1.48</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Vested restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20260101__20260630_zGR9cWOogp74" style="text-align: right" title="Vested restricted stock units">(47,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20260101__20260630_zizootHYQe46" style="text-align: right" title="Vested restricted stock units, weighted average grant date fair value">(1.63</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Forfeited restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20260101__20260630_zlIOdWp7kenh" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited restricted stock units">(425,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_iN_di_c20260101__20260630_zoJFXp0Twi8g" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited restricted stock units, weighted average grant date fair value">(1.58</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Balance of restricted stock units outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20260101__20260630_zajXu5yHYls5" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units, Outstanding Number of units, Ending Balance">125,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630_zr02rkSr1jea" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units, weighted average grant date fair value, ending balance">1.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Restricted stock unit compensation expense was $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z18zZEr93o32" title="Restricted stock unit compensation expense">42,000 and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztkfAnjur2t1" title="Restricted stock unit compensation expense">80,000 for the three months ended June 30, 2026 and 2025, respectively. Restricted stock unit compensation expense was $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDC0JeoQdT22" title="Restricted stock unit compensation expense">121,000 and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHO4blti7J43" title="Restricted stock unit compensation expense">161,000 for the six months ended June 30, 2026 and 2025, respectively. Stock-based compensation expense is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. The Company had an aggregate of $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znuyl8RyGBAi" title="Unrecognized restricted stock unit compensation expense">111,000 of unrecognized restricted stock unit compensation as of June 30, 2026 to be expensed over a weighted average period of approximately one year. All of the Company’s outstanding (unvested) restricted stock units have dividend equivalent rights. As of June 30, 2026 and December 31, 2025, there was $<span id="xdx_908_ecustom--AccruedDividendRightsOnRestrictedStockUnit_iI_pp0p0_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjqO1nHRKrP5" title="Accrued dividend rights on restricted stock unit">20,000 and $<span id="xdx_907_ecustom--AccruedDividendRightsOnRestrictedStockUnit_iI_pp0p0_c20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zg2LluIaGohg" title="Accrued dividend rights on restricted stock unit">161,000, respectively, accrued for dividend equivalent rights which were included in other accrued expenses.

125000 1920000

<table cellpadding="0" cellspacing="2" id="xdx_88C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLpGaSiEv2o4" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Schedule of stock option activity</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Grants of restricted stock units"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Grants of restricted stock units, weighted average grant date fair value"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt"> Balance of restricted stock units outstanding at December 31, 2025</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_c20260101__20260630_zTlTjiypnuBa" style="width: 12%; text-align: right" title="Restricted stock units, outstanding number of units, beginning balance">512,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260630_zOU71zXrBgF6" style="width: 12%; text-align: right" title="Restricted stock units, weighted average grant date fair value, beginning balance">1.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Grants of restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20260101__20260630_zpoKrFDXcXKc" style="text-align: right" title="Grants of restricted stock units">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--IssuanceWeightedaverageGrantDateFairValue_c20260101__20260630_zNIiRg2P1SJl" style="text-align: right" title="Grants of restricted stock units, weighted average grant date fair value">1.48</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Vested restricted stock units</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20260101__20260630_zGR9cWOogp74" style="text-align: right" title="Vested restricted stock units">(47,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_iN_di_c20260101__20260630_zizootHYQe46" style="text-align: right" title="Vested restricted stock units, weighted average grant date fair value">(1.63</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Forfeited restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_di_c20260101__20260630_zlIOdWp7kenh" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited restricted stock units">(425,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_iN_di_c20260101__20260630_zoJFXp0Twi8g" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited restricted stock units, weighted average grant date fair value">(1.58</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Balance of restricted stock units outstanding at June 30, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20260101__20260630_zajXu5yHYls5" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units, Outstanding Number of units, Ending Balance">125,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630_zr02rkSr1jea" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted stock units, weighted average grant date fair value, ending balance">1.49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

512500

1.58

85000

1.48

47500

1.63

425000

1.58

125000

1.49

42000

80000

121000

161000

111000

20000 161000

NOTE E – NET LOSS PER SHARE Basic loss per share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted per share data includes the dilutive effects of restricted stock units. Potentially dilutive shares of 125,000 and 517,500 at June 30, 2026 and 2025, respectively, consisted of outstanding restricted stock units. However, since the Company generated a net loss for the three and six months ended June 30, 2026 and 2025, potentially dilutive shares were not reflected in diluted net loss per share because the impact of such instruments was anti-dilutive. Computations of basic and diluted weighted average common shares outstanding were as follows: <table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4SnPC4BIKTj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Schedule of basic and diluted weighted average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260101__20260630_zG67m6DUPt51" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250101__20250630_zHGK2OQl3em5" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20260401__20260630_zXf3XZO50tw6" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250401__20250630_zRZPN6zkn0x9" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; font-size: 12pt; text-align: justify"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; font-size: 12pt"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zdE4Rv7z90Mh" style="vertical-align: bottom"> <td style="padding-top: 6pt; width: 40%; text-align: left">Weighted-average common shares outstanding – basic</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,824,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,883,729</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,836,456</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,873,907</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_zfRoaTsZElU5" style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Dilutive effect of restricted stock units and stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zHKVXIZck4Gh" style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Weighted-average common shares outstanding – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,824,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,883,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,836,456</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,873,907</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--RestrictedStockUnitsExcludedFromComputationOfDilutedLossPerShareBecauseEffectOfInclusionWouldHaveBeenAntidilutive_z3vKUK3MiXLi" style="vertical-align: bottom"> <td style="vertical-align: bottom; padding-top: 6pt; text-align: left">Restricted stock units excluded from the computation of diluted loss per share because the effect of inclusion would have been anti-dilutive</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">517,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">517,500</td><td style="text-align: left"> </td></tr> </table>

125000

517500

<table cellpadding="0" cellspacing="0" id="xdx_883_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4SnPC4BIKTj" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - LOSS PER SHARE (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Schedule of basic and diluted weighted average common shares outstanding</td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20260101__20260630_zG67m6DUPt51" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250101__20250630_zHGK2OQl3em5" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20260401__20260630_zXf3XZO50tw6" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20250401__20250630_zRZPN6zkn0x9" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; font-size: 12pt; text-align: justify"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 6pt; font-size: 12pt"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td><td style="font-size: 11pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 11pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 11pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zdE4Rv7z90Mh" style="vertical-align: bottom"> <td style="padding-top: 6pt; width: 40%; text-align: left">Weighted-average common shares outstanding – basic</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,824,937</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,883,729</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,836,456</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">22,873,907</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_zfRoaTsZElU5" style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Dilutive effect of restricted stock units and stock options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zHKVXIZck4Gh" style="vertical-align: bottom"> <td style="padding-top: 6pt; text-align: left">Weighted-average common shares outstanding – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,824,937</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,883,729</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,836,456</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">22,873,907</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--RestrictedStockUnitsExcludedFromComputationOfDilutedLossPerShareBecauseEffectOfInclusionWouldHaveBeenAntidilutive_z3vKUK3MiXLi" style="vertical-align: bottom"> <td style="vertical-align: bottom; padding-top: 6pt; text-align: left">Restricted stock units excluded from the computation of diluted loss per share because the effect of inclusion would have been anti-dilutive</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">517,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">517,500</td><td style="text-align: left"> </td></tr> </table>

22824937

22883729

22836456

22873907

22824937

22883729

22836456

22873907

125000 517500 125000 517500

NOTE F – FAIR VALUE MEASUREMENTS ASC Topic 820 - Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1: Observable inputs such as quoted prices (unadjusted) in an active market for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs that are supported by little or no market activity; therefore, the inputs are developed by the Company using estimates and assumptions that the Company expects a market participant would use, including pricing models, discounted cash flow methodologies, or similar techniques. The carrying value of the Company’s financial instruments, including cash and cash equivalents and accounts payable, approximates fair value because of the short-term nature of these financial instruments. The Company’s marketable securities are classified within Level 1 because they are valued using quoted market prices in an active market. The Company’s equity investment in ILiAD is measured on a non-recurring basis and is classified within Level 3 as it does not have a readily determinable value and is valued using observable price transactions for identical or similar investments of the same issuer and applying an option pricing model to adjust for differences and allocate enterprise value among ILiAD’s various classes of securities (see Note B[3] and Note K hereof). The Company estimates the fair value of its equity investment in ILiAD using an option pricing model. Volatility is a significant unobservable input because the ILiAD’s equity is not publicly traded. The volatility assumption was developed using guideline public companies in similar industries, adjusted for size and illiquidity. The expected time to a liquidity event is estimated based on management’s assessment of potential scenarios. The risk-free rate corresponds to the U.S. Treasury yield with a term matching the expected time to liquidity. A discount for lack of marketability was applied, reflecting the restricted nature of the ILiAD shares held by the Company. The resulting fair value per-share range was estimated based on scenario weighting. Increases in volatility or the expected time to liquidity, or reductions in the marketability discount, would result in a higher fair value measurement under the option pricing model. The following assumptions were used to calculate the fair value of the Company’s equity investment in ILiAD as of February 5, 2026 (since such date there have been no observable price changes in identical or similar securities of ILiAD): <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"> <tr style="vertical-align: top; text-align: left"> <td style="width: 33%">Expected volatility</td> <td style="width: 3%"> </td> <td style="width: 64%"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630_z2bU5X8whNe2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Expected volatility">85.0%</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td>Time to liquidity event</td> <td> </td> <td><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630_zNbnqdEP14fi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Time to liquidity event">2.0 years</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td>Risk-free interest rate</td> <td> </td> <td><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630_z1WK5PhKp1b2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Risk-free interest rate">3.47%</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td style="white-space: nowrap">Discount for lack of marketability</td> <td> </td> <td><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dp_c20260101__20260630__srt--RangeAxis__srt--MinimumMember_zSd4UIEkYlMe" title="Discount for lack of marketability">20% - <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_dp_c20260101__20260630__srt--RangeAxis__srt--MaximumMember_zweuHicm0eN1" title="Discount for lack of marketability">40% </td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td>Fair value per share range </td> <td> </td> <td>$1.33 - $2.65 </td></tr> </table>

0.850

P2Y

0.0347

0.20

0.40

1.33

2.65

NOTE G – MARKETABLE SECURITIES Marketable securities as of June 30, 2026 and December 31, 2025 were composed of the following: <table cellpadding="0" cellspacing="3" id="xdx_89E_eus-gaap--MarketableSecuritiesTextBlock_zr5UydqrI26i" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - MARKETABLE SECURITIES (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Schedule of marketable securities</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Cost Basis</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Unrealized Gains</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Unrealized Losses</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Fair Value</td><td style="font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; width: 40%; text-align: left; padding-left: 5.4pt">Government securities</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zastfHlVnEh9" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">13,583,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zMSV35l9xWIi" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">86,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zYm0yIkayDp7" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">(204,000</td><td style="padding-top: 5pt; width: 1%; text-align: left">)</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zC9ltmBmAe6f" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">13,465,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Fixed income mutual funds</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zGZKF2Z0oVk8" style="padding-top: 5pt; text-align: right" title="Government securities">8,039,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zm4pJBPFfaDh" style="padding-top: 5pt; text-align: right" title="Government securities">143,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zgyNFJoPM3Tg" style="padding-top: 5pt; text-align: right" title="Government securities">(92,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98E_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_z2vv7hnjNR47" style="padding-top: 5pt; text-align: right" title="Fixed income mutual funds">8,090,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt">Certificates of deposit</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_986_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zzFECFpamC6g" style="padding-top: 5pt; text-align: right" title="Government securities">752,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_983_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zQ5D0N6IO7Y4" style="padding-top: 5pt; text-align: right" title="Government securities">2,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98A_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zVT96rG65vr7" style="padding-top: 5pt; text-align: right" title="Government securities">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zuxioWVzv9dl" style="padding-top: 5pt; text-align: right" title="Certificates of deposit">754,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Corporate bonds and notes</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_980_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zJFpuZ2fivo7" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">2,027,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zbbohZuabCVl" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zqbpbXfw3wd5" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">(19,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_988_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zFJiCMH4gxX5" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Corporate bonds and notes">2,008,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Total marketable securities</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_982_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zEQ8EhuFggu4" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">24,401,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_987_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zd1S1l0Zfts6" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">231,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_984_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_z4GSoBjid2hl" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">(315,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98D_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zN5MmIiRReD1" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">24,317,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="3" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - MARKETABLE SECURITIES (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-bottom: 1pt; text-align: justify"> </td><td style="padding-top: 5pt; padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center"> December 31, 2025</td><td style="padding-top: 5pt; padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: justify"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Unrealized Losses</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Fair Value</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; width: 40%; text-align: left; padding-left: 5.4pt">Government securities</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zDGYPrDFjZG1" style="padding-top: 5pt; width: 10%; text-align: right">12,576,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zqiqilsKEkIf" style="padding-top: 5pt; width: 10%; text-align: right">95,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zbysTx1K7lm8" style="padding-top: 5pt; width: 10%; text-align: right">(46,000</td><td style="padding-top: 5pt; width: 1%; text-align: left">)</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zZcMQp6d3YK1" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">12,625,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Fixed income mutual funds</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_982_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_ziph8fRzmZLl" style="padding-top: 5pt; text-align: right">7,855,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zx1TGsU7MPVh" style="padding-top: 5pt; text-align: right">228,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_z6TUFT6mRtB9" style="padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zjuontbBFwr8" style="padding-top: 5pt; text-align: right" title="Fixed income mutual funds">8,083,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt">Certificates of deposit</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_985_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zVc3fmRf6LJh" style="padding-top: 5pt; text-align: right">752,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_988_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zzxE44U1NLSj" style="padding-top: 5pt; text-align: right">7,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_980_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zrPIgU3imHph" style="padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_985_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_z6CoixzShlw1" style="padding-top: 5pt; text-align: right" title="Certificates of deposit">759,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Corporate bonds and notes</td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_982_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zNAnv4bB97Vg" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">2,027,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_986_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zhTcKzlpIBl4" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_987_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zSOwWYFg06a2" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">(27,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left">)</td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_987_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zdLniKiHEivf" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Corporate bonds and notes">2,000,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Total marketable securities</td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98C_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zzNbKHNFm7W5" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">23,210,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98F_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zI0NCmHHPYPb" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">330,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_985_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zf5Sy7buBtdh" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">(73,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98B_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zVQO85ozoxki" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Total marketable securities">23,467,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> </table> The Company’s marketable securities are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in an active market.

<table cellpadding="0" cellspacing="3" id="xdx_89E_eus-gaap--MarketableSecuritiesTextBlock_zr5UydqrI26i" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - MARKETABLE SECURITIES (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Schedule of marketable securities</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right" title="Government securities"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: justify"> </td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-size: 12pt; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Cost Basis</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Unrealized Gains</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Unrealized Losses</td><td style="font-size: 12pt; font-weight: bold"> </td><td style="font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="font-size: 12pt; font-weight: bold; text-align: center">Fair Value</td><td style="font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; text-align: right"> </td><td style="padding-top: 5pt; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; width: 40%; text-align: left; padding-left: 5.4pt">Government securities</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zastfHlVnEh9" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">13,583,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zMSV35l9xWIi" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">86,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zYm0yIkayDp7" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">(204,000</td><td style="padding-top: 5pt; width: 1%; text-align: left">)</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--GovernmentSecurities_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zC9ltmBmAe6f" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">13,465,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Fixed income mutual funds</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zGZKF2Z0oVk8" style="padding-top: 5pt; text-align: right" title="Government securities">8,039,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zm4pJBPFfaDh" style="padding-top: 5pt; text-align: right" title="Government securities">143,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zgyNFJoPM3Tg" style="padding-top: 5pt; text-align: right" title="Government securities">(92,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98E_ecustom--ShortTermBondFunds_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_z2vv7hnjNR47" style="padding-top: 5pt; text-align: right" title="Fixed income mutual funds">8,090,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt">Certificates of deposit</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_986_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zzFECFpamC6g" style="padding-top: 5pt; text-align: right" title="Government securities">752,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_983_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zQ5D0N6IO7Y4" style="padding-top: 5pt; text-align: right" title="Government securities">2,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98A_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zVT96rG65vr7" style="padding-top: 5pt; text-align: right" title="Government securities">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CertificatesOfDeposit_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zuxioWVzv9dl" style="padding-top: 5pt; text-align: right" title="Certificates of deposit">754,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Corporate bonds and notes</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_980_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zJFpuZ2fivo7" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">2,027,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zbbohZuabCVl" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_98F_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zqbpbXfw3wd5" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Government securities">(19,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_988_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zFJiCMH4gxX5" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Corporate bonds and notes">2,008,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Total marketable securities</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_982_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zEQ8EhuFggu4" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">24,401,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_987_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zd1S1l0Zfts6" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">231,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_984_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_z4GSoBjid2hl" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">(315,000</td><td style="padding-top: 5pt; text-align: left">)</td><td style="padding-top: 5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98D_ecustom--OtherInvestment_iI_pp0p0_c20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zN5MmIiRReD1" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Government securities">24,317,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="3" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - MARKETABLE SECURITIES (Details)"> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-bottom: 1pt; text-align: justify"> </td><td style="padding-top: 5pt; padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center"> December 31, 2025</td><td style="padding-top: 5pt; padding-bottom: 1pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: justify"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Cost Basis</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Unrealized Gains</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Unrealized Losses</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td> <td colspan="2" style="padding-top: 5pt; font-size: 12pt; font-weight: bold; text-align: center">Fair Value</td><td style="padding-top: 5pt; font-size: 12pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; width: 40%; text-align: left; padding-left: 5.4pt">Government securities</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zDGYPrDFjZG1" style="padding-top: 5pt; width: 10%; text-align: right">12,576,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zqiqilsKEkIf" style="padding-top: 5pt; width: 10%; text-align: right">95,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zbysTx1K7lm8" style="padding-top: 5pt; width: 10%; text-align: right">(46,000</td><td style="padding-top: 5pt; width: 1%; text-align: left">)</td><td style="padding-top: 5pt; width: 3%"> </td> <td style="padding-top: 5pt; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--GovernmentSecurities_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zZcMQp6d3YK1" style="padding-top: 5pt; width: 10%; text-align: right" title="Government securities">12,625,000</td><td style="padding-top: 5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-left: 5.4pt">Fixed income mutual funds</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_982_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_ziph8fRzmZLl" style="padding-top: 5pt; text-align: right">7,855,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zx1TGsU7MPVh" style="padding-top: 5pt; text-align: right">228,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_98B_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_z6TUFT6mRtB9" style="padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShortTermBondFunds_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zjuontbBFwr8" style="padding-top: 5pt; text-align: right" title="Fixed income mutual funds">8,083,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt">Certificates of deposit</td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_985_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zVc3fmRf6LJh" style="padding-top: 5pt; text-align: right">752,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_988_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zzxE44U1NLSj" style="padding-top: 5pt; text-align: right">7,000</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_980_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zrPIgU3imHph" style="padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td id="xdx_985_ecustom--CertificatesOfDeposit_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_z6CoixzShlw1" style="padding-top: 5pt; text-align: right" title="Certificates of deposit">759,000</td><td style="padding-top: 5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Corporate bonds and notes</td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_982_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zNAnv4bB97Vg" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">2,027,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_986_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zhTcKzlpIBl4" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">–</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_987_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zSOwWYFg06a2" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right">(27,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left">)</td><td style="padding-top: 5pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: left"> </td><td id="xdx_987_ecustom--CorporateBondsAndNotes_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zdLniKiHEivf" style="border-bottom: Black 1pt solid; padding-top: 5pt; text-align: right" title="Corporate bonds and notes">2,000,000</td><td style="padding-top: 5pt; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"> Total marketable securities</td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98C_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--CostBasisMember_zzNbKHNFm7W5" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">23,210,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98F_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedGainsMember_zI0NCmHHPYPb" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">330,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_985_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--InvestmentIssuerNameAxis__custom--GrossUnrealizedLossesMember_zf5Sy7buBtdh" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right">(73,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-top: 5pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: left">$</td><td id="xdx_98B_ecustom--OtherInvestment_iI_pp0p0_c20251231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--FairValueMember_zVQO85ozoxki" style="border-bottom: Black 2.5pt double; padding-top: 5pt; text-align: right" title="Total marketable securities">23,467,000</td><td style="padding-top: 5pt; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-top: 5pt; padding-left: 5.4pt"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt"> </td> <td style="padding-top: 5pt; text-align: left"> </td><td style="padding-top: 5pt; text-align: right"> </td><td style="padding-top: 5pt; text-align: left"> </td></tr> </table>

13583000 86000 -204000 13465000 8039000 143000 -92000 8090000 752000 2000 754000 2027000 -19000 2008000 24401000 231000 -315000 24317000 12576000 95000 -46000 12625000 7855000 228000 8083000 752000 7000 759000 2027000 -27000 2000000 23210000 330000 -73000 23467000

NOTE H – COMMITMENTS AND CONTINGENCIES [1]      Legal Fees The Company engages law firms with respect to its patent litigation on a full contingency basis ranging from 15-40% (with certain exceptions) of the net recovery (after deduction of expenses) depending on the stage of the proceeding in which the result (settlement or judgment) is achieved. The Company is responsible for all or a portion of the expenses incurred with respect to such litigation. With respect to proceedings at the U.S Patent and Trademark Office, the Company engages law firms on a fixed fee basis. [2]      Patent Acquisition On March 31, 2025, the Company acquired its Smart Home Patent Portfolio from IoT and M2M Technologies, LLC for a purchase price of $400,000. In addition, the Company is obligated to pay the seller an additional $50,000 upon certain events. The Company is also obligated to pay the seller 12.5% of the first $100 million of net proceeds (after the deduction of expenses) and 5% of the net proceeds in excess of $100 million from Monetization Activities (as defined) related to the patent portfolio. In connection with the Company’s acquisition of its HFT Patent Portfolio in March 2022, the Company paid the seller $<span id="xdx_901_ecustom--ObligationToPayHftSellerAdditionalCashBasedOnAchievingCertainMilestones_pp0p0_c20260101__20260630_zStzxydWb44g" title="Obligation to pay HFT seller additional cash based on achieving certain milestones">500,000 in cash and had a contingent obligation to pay $<span id="xdx_90B_ecustom--ObligationToPayHftSellerAdditionalCashBasedOnAchievingCertainMilestones_pp0p0_c20260101__20260630_zAqHRhBjLND6" title="Obligation to pay HFT seller additional cash based on achieving certain milestones">500,000 and issue $375,000 of the Company’s common stock (up to a maximum of 375,000 shares) upon achieving certain milestones with respect to the HFT Patent Portfolio. The Company also has a contingent obligation to pay the seller 15% of the first $50 million of net proceeds (after deduction of expenses) generated by the HFT Patent Portfolio and 17.5% of net proceeds greater than $50 million. During the six months ended June 30, 2026, a milestone was achieved which entitled the seller to receive $250,000 in cash and $125,000 of the Company’s common stock (94,778 shares). This contingent purchase price of $375,000 was capitalized and amortized over the remaining useful life of the underlying patents and recorded in patents, net of accumulated amortization on the Company’s unaudited condensed consolidated balance sheet. In connection with the Company’s acquisition of its Cox Patent Portfolio in February 2013, the Company is obligated to pay Dr. Cox 12.5% of the net proceeds (after deduction of expenses) generated by the Company from licensing, sale or enforcement of the patent portfolio. In connection with the Company’s acquisition of its M2M/IoT Patent Portfolio in December 2017, the Company is obligated to pay the seller 14% of the first $100 million of net proceeds (after deduction of expenses) and 5% of net proceeds greater than $100 million from Monetization Activities (as defined) related to the patent portfolio. In addition, the seller will be entitled to receive from the Company $250,000 of additional consideration upon the occurrence of certain future events related to the patent portfolio. [3]      Leases The Company has one operating lease for its principal office space in New Canaan, Connecticut that was extended through September 30, 2026. There are no material residual guarantees associated with the Company’s lease and there are no significant restrictions or covenants included in the Company’s lease agreement. The table below presents certain information related to the Company’s lease costs for the period ended: <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zKOHA9fBcI8i" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left">Schedule of lease cost</td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_49F_20260101__20260630_z6D40buxWCjd" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_497_20250101__20250630_zWBBKlTmGvjj" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_494_20260401__20260630_z6H5YxADW726" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt"> </td> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td id="xdx_499_20250401__20250630_zXU8L7ylY5O" style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: center"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">Six Months Ended June 30,</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">Three Months Ended June 30,</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_maCz3yQ_zvoEFIpr9yoj" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 40%; text-align: left">Operating lease cost</td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">–</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">27,000</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">–</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 3%"> </td> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 1%; text-align: left">$</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 10%; text-align: right">5,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maCz3yQ_zS21SsOmJR5h" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">36,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">12,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">18,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">12,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LeaseCost_maCz3yQ_z29th55DdcFi" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> Total</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">36,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">39,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">18,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">17,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.15 0.40 400000 50000 0.125 0.05 500000 500000 500000 375000 0.15 0.175 250000 125000 0.125 0.14 0.05 250000

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--LeaseCostTableTextBlock_zKOHA9fBcI8i" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left">Schedule of lease cost</td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_49F_20260101__20260630_z6D40buxWCjd" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_497_20250101__20250630_zWBBKlTmGvjj" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="padding-top: 6pt"> </td> <td style="padding-top: 6pt; text-align: left"> </td><td id="xdx_494_20260401__20260630_z6H5YxADW726" style="padding-top: 6pt; text-align: center"> </td><td style="padding-top: 6pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt"> </td> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td id="xdx_499_20250401__20250630_zXU8L7ylY5O" style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: center"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">Six Months Ended June 30,</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">Three Months Ended June 30,</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 12pt Times New Roman, Times, Serif"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 11pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 11pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeaseCost_maCz3yQ_zvoEFIpr9yoj" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 40%; text-align: left">Operating lease cost</td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">–</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">27,000</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="padding-top: 6pt; width: 3%"> </td> <td style="padding-top: 6pt; width: 1%; text-align: left">$</td><td style="padding-top: 6pt; width: 10%; text-align: right">–</td><td style="padding-top: 6pt; width: 1%; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 3%"> </td> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 1%; text-align: left">$</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 10%; text-align: right">5,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ShortTermLeaseCost_maCz3yQ_zS21SsOmJR5h" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left; padding-bottom: 1pt">Short-term lease cost</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">36,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">12,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">18,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; text-align: right">12,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-top: 6pt; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LeaseCost_maCz3yQ_z29th55DdcFi" style="vertical-align: bottom"> <td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> Total</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">36,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">39,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">18,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 11pt Times New Roman, Times, Serif; text-align: right">17,000</td><td style="font: 11pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

27000

5000

36000

12000

18000

12000

36000

39000

18000

17000

NOTE I - EMPLOYMENT ARRANGEMENTS AND OTHER AGREEMENTS On March 22, 2022, the Company entered into an employment agreement with its Chairman and Chief Executive Officer for a four-year term (“Term”), which among other things, included an annual base salary of $<span id="xdx_900_eus-gaap--SalariesWagesAndOfficersCompensation_pp0p0_c20220301__20220322__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--PriorEmploymentAgreementMember_zeyvoNbpHRwh" title="Annual base salary">535,000 which was increased by <span id="xdx_90E_ecustom--AnnualBaseSalaryIncrease_dp_c20220301__20220322__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--PriorEmploymentAgreementMember_zVJhUxXZz6z1" title="Annual base salary increase">3% per annum during the Term, a discretionary annual bonus, an equity grant and certain incentive compensation. The Company’s Compensation Committee and the Chairman and Chief Executive Officer are currently discussing the terms of a new employment agreement while the Chairman and Chief Executive Officer continues to serve in such capacity. Under the surviving terms of the prior employment agreement, so long as our Chairman and Chief Executive Officer continues to serve as an executive officer of the Company, whether pursuant to the Agreement or otherwise, he shall also receive incentive compensation in an amount equal to 5% of our gross royalties or other payments from Licensing Activities (as defined) (without deduction of legal fees or any other expenses) with respect to our Remote Power Patent and a 10% net interest (gross royalties and other payments after deduction of all legal fees and litigation expenses related to licensing, enforcement and sale activities, but in no event shall he receive less than 6.25% of the gross recovery) of our royalties and other payments relating to Licensing Activities with respect to patents other than our Remote Power Patent (including all of our existing patent portfolios and our investment in ILiAD). In the event of a merger or sale of substantially all of our assets, we have the option to extinguish the right of our Chairman and Chief Executive Officer to receive future Incentive Compensation by payment to him of a lump sum payment, in an amount equal to the fair market value of such future interest as determined by an independent third party expert if the parties do not reach agreement as to such value.

535000

0.03

NOTE J – LEGAL PROCEEDINGS <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">[1]</td><td style="text-align: justify">On September 8, 2025, the Company’s wholly-owned subsidiary, HFT Solutions, LLC, commenced patent litigation against Optiver US, LLC and Optiver Trading US, LLC (“Optiver”) in the United States District Court for the Western District of Texas for infringement of certain patents within the Company’s HFT Patent Portfolio. On November 21, 2025, the Optiver defendants filed their answer and counterclaims of non-infringement and invalidity of the asserted patents.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">[2]</td><td style="text-align: justify">On June 27, 2025, the Company commenced patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. (collectively, “Samsung”) in the United States District Court for the Eastern District of Texas, Marshall Division, for infringement of six patents within the Company’s M2M/IoT Patent Portfolio. The lawsuit alleges that Samsung infringes the Company patents by supporting certain eSIM (embedded Subscriber Identification Module) and certain 5G technologies in its mobile devices, including its Galaxy smartphones, watches and tablets. A trial date has been scheduled for June 7, 2027. In April and May 2026, the U.S. Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office denied the institution, on the merits, of six Inter Partes Review proceedings requested by Samsung, relating to all six patents being asserted by the Company in the litigation. </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">[3]</td><td style="text-align: justify">On December 24, 2024, the Company’s wholly-owned subsidiary, HFT Solutions, LLC, initiated patent litigations against Citadel Securities, LLC (“Citadel”) and Jump Trading, LLC (“Jump”) in the United States District Court for the Northern District of Illinois for infringement of certain patents within our HFT Patent Portfolio. In the Citadel action, on April 7, 2025, the defendant Citadel filed a motion to dismiss under 35 U.S.C. § 101, asserting that the asserted patents are directed to patent-ineligible subject matter. On December 1, 2025, the Court denied Citadel’s motion to dismiss. On January 5, 2026, Citadel filed its answer asserting defenses of non- infringement, patent validity and counterclaims for the same. On April 7, 2025, defendant Jump filed an answer and counterclaims of non-infringement and invalidity of the asserted patents. On May 19, 2026 and June 2, 2026, the PTAB denied institution of two IPRs filed by Citadel with respect to two of the patents asserted by the Company against Citadel in the litigation. On July 1, 2026, the Company dismissed without prejudice its patent infringement case against Jump. Depending upon future developments in the industry or otherwise, the Company may decide to revisit potential IP causes of action against Jump in order to protect its intellectual property rights.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 24pt">[4]</td><td style="text-align: justify">On April 4, 2014 and December 3, 2014, the Company initiated litigation against Google Inc. (“Google”) and YouTube, LLC (“YouTube”) in the U.S. District Court for the Southern District of New York for infringement of several of its patents within its Cox Patent Portfolio which relate to the identification of media content on the Internet. The lawsuit alleges that Google and YouTube have infringed and continue to infringe certain of the Company’s patents by making, using, selling and offering to sell unlicensed systems and related products and services, which include YouTube’s Content ID system. In April 2024, following a motion for summary judgment by defendants, the U.S. District Court for the Southern District of New York issued a judgment dismissing the Company’s patent infringement claims.</td></tr></table> On May 14, 2024, the Company filed a notice of appeal to the U. S. Court of Appeals for the Federal Circuit. On April 23, 2026, the U.S. Court of Appeals for the Federal Circuit issued a decision on the appeal overturning the judgment of non-infringement of the U.S District Court for the Southern District of New York relating to the Company’s Patent No. 8,205,237 (the “ ’237 Patent ”) for certain implementations of Google’s Content ID system. The Federal Circuit also affirmed the District Court’s judgement that (i) certain claims in other asserted patents were invalid, and (ii) a previous implementation of Content ID does not infringe the claims of the ’237 Patent. The Federal Circuit remanded the case to the District Court for further proceedings on the infringement case consistent with its decision. A trial date has been scheduled for December 7, 2026.

NOTE K – EQUITY INVESTMENTS During the period December 2018 through August 2022, the Company made aggregate investments of $7,000,000 in ILiAD, a privately held clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. ILiAD is focused on validating its proprietary intranasal vaccine, BPZE1, for the prevention of pertussis (whooping cough). In connection with its initial investment, the Company’s Chairman and Chief Executive Officer obtained a seat on ILiAD’s Board of Managers. These investments were accounted for under the equity method of accounting in accordance with ASC 323 (see Note B[3]). On February 5, 2026, ILiAD completed a $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20260204__20260205__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHFB0bnlXFvl" title="Issued preferred stock, value">115,000,000 Series B preferred stock financing (the “Financing”). As part of the Financing, ILiAD converted from a limited liability company to a corporation. Following the closing of the Financing, ILiAD’s Board was reconstituted and the Company’s Chairman and Chief Executive officer no longer serves on the Board of ILiAD. As a result of ILiAD’s closing of the Financing and the conversion to a corporation, as of February 5, 2026 the Company no longer accounted for its investment in ILiAD using the equity method, under which the Company recorded its proportionate share of ILiAD’s losses each reporting period, and adopted the cost value method of accounting in accordance with ASC 321. Under this guidance, investments in equity securities in privately-held companies without readily determinable fair values are generally recorded at cost, plus or minus subsequent observable price changes in identical or similar investments, less impairments (see Note B[3] hereof). Since February 5, 2026 (the closing date of the Financing), there have been no observable price changes in identical or similar securities of ILiAD. As a result of an observable price change due to the Financing discussed above, the equity investment was remeasured during the six month period ended June 30, 2026 and the Company recorded an increase of $1,052,000 in the carrying value of its equity investment in ILiAD and recognized a corresponding gain of $<span id="xdx_90E_eus-gaap--EquityMethodInvestmentDeferredGainOnSale_c20260101__20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zT0vfyKFioOj" title="Equity investment corresponding gain">1,052,000, which is included in “Other income – Gain on equity investment” in its unaudited condensed consolidated statements of operations. After the closing of the Financing and on June 30, 2026, the Company holds 2,054,507 shares of common stock, 262,908 shares of Series A preferred stock and 319,789 shares of Series A-1 preferred stock, representing approximately 2.5% of the outstanding securities of ILiAD on a fully diluted basis. The Company evaluated the Financing and determined that it represented an orderly transaction for a similar investment of the same issuer. To estimate the fair value of its common stock, Series A preferred stock and Series A-1 preferred stock for purpose of remeasuring the carrying value of the investment, the Company considered the transaction price of the Series B preferred stock in the Financing and made adjustments, as necessary, to reflect differences in liquidation preferences, dividend rights, conversion features and other terms as compared to the classes of equity held by the Company. The Company applied a valuation model consistent with a market approach, which included the use of an option pricing model to allocate enterprise value among ILiAD’s various classes of equity (see Note F). The Company has elected the practical expedient permitted by ASC 321, recorded the above equity investment on a cost basis and will continue to monitor the equity investment for impairment and additional observable price changes in future reporting periods.

7000000

115000000

1052000

2054507

262908

319789

0.025

NOTE L – STOCK REPURCHASES On June 17, 2025, the Board of Directors authorized an extension and increase of the Company’s share repurchase program (the “Share Repurchase Program”) to repurchase up to $5,000,000 of common stock over the subsequent 24 month period. The common stock may be repurchased from time to time in open market transactions or privately negotiated transactions at the Company’s discretion except for repurchases under the Company’s 10b5-1 plans. The timing and amount of the shares repurchased is determined by management, except for repurchases under the Company’s 10b5-1 plans, based on its evaluation of market conditions and other factors. The Share Repurchase Program may be increased, suspended or discontinued at any time. Since inception of the Share Repurchase Program in August 2011 through June 30, 2026, the Company has repurchased an aggregate of 10,682,470 shares of its common stock at an aggregate cost of $20,402,985 (exclusive of commissions) or an average per share price of $1.91. During the three months ended June 30, 2026, the Company repurchased an aggregate of 34,980 shares of its common stock at an aggregate cost of $50,333 (exclusive of commissions ) or an average per share price of $1.44. During the six months ended June 30, 2026, the Company repurchased an aggregate of 95,976 shares of its common stock at an aggregate cost of $133,014 (exclusive of commissions) or an average per share price of $1.39. On June 29 2026, the Company entered into a written trading plan (the “10b5-1 Plan”) under Rule 10b5-1 of the Securities Exchange Act of 1934 (the “Exchange Act”). Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading black-outs or pursuant to insider trading laws. Purchases under the 10b5-1 Plan may be made during the following periods: (1) beginning on July 10, 2026 until two trading days after the Company issues a press release announcing its financial results for the quarter ended June 30, 2026, and (2) beginning on October 1, 2026 until two trading days after the Company issues a press release announcing its financial results for the quarter ended September 30, 2026. Under the 10b5-1 Plan, the Company’s third party broker may purchase up to 500,000 shares of the Company’s common stock, subject to certain price, market, volume and timing constraints, in accordance with the terms of the plan and subject to Rule 10b5-1 and Rule 10b-18 of the Exchange Act. On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations occurring on or after January 1, 2023. The amount of the excise tax is generally 1% of the net fair market value of the net shares repurchased (repurchases net of new share issuances) at the time of the repurchase. The excise tax applies in cases where the total value of the stock repurchased during the taxable year exceeds $1,000,000. During the three and six months ended June 30, 2026 and 2025, the Company did not incur such excise tax. At June 30, 2026, the dollar value of remaining shares that may be repurchased under the Share Repurchase Program was $4,777,417.

5000000

10682470

20402985

1.91

34980

50333

1.44

95976

133014

1.39 500000 the stock repurchased during the taxable year exceeds $1,000,000

4777417

NOTE M – CONCENTRATIONS OF CREDIT RISK The Company maintains cash and certificates of deposit in accounts at financial institutions. The accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. At June 30, 2026 and December 31, 2025, the Company had $4,000 and $9,000, respectively, of cash and certificates of deposit in excess of the FDIC insured limit. The Company maintains cash equivalents in brokerage accounts at financial institutions. At June 30, 2026 and December 31, 2025, the Company had cash equivalents of $9,221,000 and $13,302,000, respectively, in these brokerage accounts.

250000

4000

9000

9221000

13302000

NOTE N – DIVIDEND POLICY The Company’s dividend policy consists of semi-annual cash dividends of $0.05 per share ($0.10 per share annually) anticipated to be paid in March and September of each year. The Company has paid semi-annual cash dividends consistent with its policy. The Company’s dividend policy undergoes a periodic review by the Board of Directors and is subject to change at any time depending upon the Company’s earnings, financial requirements and other factors existing at the time.

0.05 0.10 false false false false